<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00079235</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-01810</org_study_id>
    <secondary_id>N0323</secondary_id>
    <secondary_id>CDR0000355117</secondary_id>
    <secondary_id>NCCTG-N0323</secondary_id>
    <secondary_id>U10CA025224</secondary_id>
    <nct_id>NCT00079235</nct_id>
  </id_info>
  <brief_title>CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II Study of the mTOR Inhibitor, CCI-779 in Patients With Advanced Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well CCI-779 works in treating patients with stage IIIB&#xD;
      non small cell lung cancer (with pleural effusion) or stage IV non-small cell lung cancer.&#xD;
      Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from&#xD;
      dividing so they stop growing or die. CCI-779 may also stop the growth of tumor cells by&#xD;
      blocking the enzymes necessary for their growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: Primary I. Determine the response rate in patients with stage IIIB (with pleural&#xD;
      effusion) or IV non-small cell lung cancer treated with CCI-779.&#xD;
&#xD;
      II. Determine the clinical toxic effects of this drug in these patients.&#xD;
&#xD;
      Secondary I. Determine the 24-week progression-free survival rate in patients treated with&#xD;
      this drug.&#xD;
&#xD;
      II. Determine the time to progression and overall survival of patients treated with this&#xD;
      drug.&#xD;
&#xD;
      III. Evaluate predictive markers of activity (e.g., PTEN mutations and phosphoAkt expression)&#xD;
      of this drug in these patients.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28&#xD;
      days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 6 months for up to 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 25-55 patients will be accrued for this study within 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed tumor response according to the Response Evaluation Criteria in Solid Tumors (RECIST)</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Confidence intervals for the true success proportion will be calculated using the Duffy-Santner approach.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>24 weeks</time_frame>
    <description>Computed and binomial confidence intervals for the true success proportion will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival time</measure>
    <time_frame>Time from registration to death due to any cause, assessed up to 5 years</time_frame>
    <description>Estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Time from registration to documentation of disease progression, assessed up to 5 years</time_frame>
    <description>Estimated using the method of Kaplan-Meier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CCI-779 on mTOR as assessed by expression of 4EBP, phosphoAkt, p70S6kinase, eIF4E, cyclinD1, Her2, and EGFR</measure>
    <time_frame>Day 8</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Stage IIIB Non-small Cell Lung Cancer</condition>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CCI-779 IV over 30 minutes on days 1, 8, 15, and 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <other_name>CCI-779</other_name>
    <other_name>cell cycle inhibitor 779</other_name>
    <other_name>Torisel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)&#xD;
&#xD;
               -  Stage IIIB (with pleural effusion) or IV disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 lesion ≥ 2.0 cm by conventional techniques OR ≥ 1.0 cm by spiral CT&#xD;
                  scan&#xD;
&#xD;
               -  The following are not considered measurable disease:&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Inflammatory breast disease&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
                    -  Abdominal masses that are not confirmed and followed by imaging techniques&#xD;
&#xD;
          -  Blood and tissue blocks available&#xD;
&#xD;
          -  Must have accessible tumor (i.e., superficial lesions such as lymph node, subcutaneous&#xD;
             nodules) to provide core needle biopsy tissue before and during study treatment&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 3 times ULN (5 times ULN if hepatic metastases are present)&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
          -  Serum fasting cholesterol ≤ 350 mg/dL&#xD;
&#xD;
          -  Serum fasting triglycerides ≤ 400 mg/dL&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No uncontrolled infection&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated basal cell or&#xD;
             squamous cell skin cancer or non-invasive carcinomas&#xD;
&#xD;
          -  No concurrent severe underlying disease that would preclude study participation&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             treatment&#xD;
&#xD;
          -  No prior biologic therapy&#xD;
&#xD;
          -  No prior gene therapy&#xD;
&#xD;
          -  No prior immunotherapy&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent prophylactic growth factors to support neutrophil count&#xD;
&#xD;
          -  No prior chemotherapy for NSCLC except low-dose cisplatin as a radiosensitizer&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  No concurrent dexamethasone (10 mg IV)&#xD;
&#xD;
          -  No prior radiotherapy to 30% or more of bone marrow&#xD;
&#xD;
          -  Concurrent radiotherapy for underlying malignancy and non-target sites (e.g., painful&#xD;
             pre-existing bony metastasis) allowed&#xD;
&#xD;
          -  No other concurrent investigational therapy&#xD;
&#xD;
          -  No concurrent immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alex Adjei</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Central Cancer Treatment Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Central Cancer Treatment Group</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>March 8, 2004</study_first_submitted>
  <study_first_submitted_qc>March 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2004</study_first_posted>
  <last_update_submitted>July 15, 2013</last_update_submitted>
  <last_update_submitted_qc>July 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

